Browse drugs

… with an objective response.Conclusions mKRAS-VAX combined with ipilimumab and nivolumab was well-tolerated and resulted in clinical respo…

…notherapy. The IGNYTE trial showed that RP1 in combination with nivolumab (nivo) demonstrated clinically meaningful, durable responses (o…

…on of any PIP-related (target-dependent) toxicities.Conclusions PIP-MMAE demonstrates robust efficacy across various solid tumors, along…

…nterpart in a single dose pharmacokinetic study in balb/c mice. ADoBind antibody exhibited a more effective ADCC than its monomeric IgG…

…. Within the treatment group 31% were treated with single agent Prednisolone (n 26), 10% were treated with MTX (n 12), 11% were treated with…

…nclusions SCIg is at least equivalent in thromboembolic risk to IVIg and may be safer for patients with existing vascular risk facto…

…ssants will be considered: agomelatine, alaproclate, bupropion, citalopram, desvenlafaxine, duloxetine, edivoxetine, escitalopram, fluoxet…

…ngle-arm trials. Fourteen studies evaluated biologic therapies: infliximab (n=5), adalimumab (n=2), etanercept (n=2), golimumab (n=1), rit…

…29 children had significant IBD clinical symptoms when starting Ustekinumab. 16/20 (80%) saw some improvements at 3 months. At 6 months 8/2…

…e contraction in response to various vasoconstrictors including noradrenaline (NA; 1x10 -9 to 3x10-4 M), phenylephrine (PE; 1x10-9 to 3x10-4 …

…10.Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L. Re-routing infliximab therapy: subcutaneous infliximab opens a path towards greater c…

…ltered cell proliferation and ferroptosis phenotypes induced by TRIM69 knockdown (IDDF2026-ABS-0282 Figure 5. TRIM69 inhibits cell pro…